Compare DCO & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCO | SLN |
|---|---|---|
| Founded | 1849 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 318.4M |
| IPO Year | N/A | N/A |
| Metric | DCO | SLN |
|---|---|---|
| Price | $93.00 | $6.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $117.80 | $39.67 |
| AVG Volume (30 Days) | 95.1K | ★ 314.1K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $806,224,000.00 | $25,830,000.00 |
| Revenue This Year | $6.10 | N/A |
| Revenue Next Year | $8.13 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 3.17 | ★ 40.39 |
| 52 Week Low | $51.76 | $1.97 |
| 52 Week High | $101.47 | $8.08 |
| Indicator | DCO | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 54.27 | 51.32 |
| Support Level | $91.35 | $6.15 |
| Resistance Level | $98.45 | $6.60 |
| Average True Range (ATR) | 2.86 | 0.54 |
| MACD | 0.55 | -0.02 |
| Stochastic Oscillator | 46.36 | 44.72 |
Ducommun Inc provides engineering & manufacturing services for high-performance products & high-cost-of failure applications used in the aerospace and defense, industrial, medical & other industries. The company's reportable segments are Structural Systems & Electronic Systems. Structural Systems designs, engineers and manufactures various sizes of complex contoured aerostructure components and assemblies and supplies composite and metal bonded structures and assemblies. Electronic Systems designs, engineers and manufactures high-reliability electronic and electromechanical products used in technology-driven markets including A&D and Industrial end-use markets. It generates maximum of its revenue from the Electronic Systems.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.